Hence, S1P1 agonists and S1P2 antagonists could provide a new strategy for managing COVID‐19 by regulating the exaggerated inflammatory response against SARS‐CoV‐2 infection and the related endothelial dysfunction and stimulated inflammatory signaling pathways [19]. Here, S1PR2 is linked to endothelial dysfunction.